TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of an Intra-articular Injection of Botulinum Toxin A Associated With Splinting for Base-of-thumb Osteoarthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years old~* Pain intensity on a self-administered 11-point pain numeric rating scale ≥ 30~* Pain involving the base-of-thumb~* X-ray evidence of base-of-thumb osteoarthritis with at least 2 of the 4 following items involving the trapeziometacarpal joint : osteophytes, joint space narrowing, subchondral bone sclerosis or subchondral cysts~* 1990 American College of Rheumatology classification criteria for hand osteoarthritis adapted to base-of-thumb osteoarthritis~* Medical examination~* Written consent~* Health insurance~* For women of childbearing age, a negative urinary pregnancy test~Exclusion Criteria:~* History of thumb surgery~* History of inflammatory or crystal-associated rheumatic disease~* Neurological disorders involving the hands other than carpien canal syndrom~* Collagen disorders involving the hands : Dupuytren, Marfan or Ehlers-Danlos diseases~* Osteoarthritis predominating at the scaphotrapezial joint on X-Ray~* Hand or wrist trauma ≤ 2 months~* Hand or wrist intra-articular injections ≤ 2 months~* Contra-indication to botulinum toxin A injection or to splinting~* Cognitive or behavioral disorders making the assessment impossible~* Participant unable to speak, read and write french~* Bilateral BTOA without predominant symptomatic side~* Pregnancy and breast feeding~* Persons referred to in Articles L 1121-5; 6; 8; 9 of the Public Health Code (protected minors or adults, guardianship or trusteeship, etc.)~* Patient with epilepsy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intra-articular botulinum toxin A and splinting (Type: EXPERIMENTAL): Ultrasound-guided injection of 50 Allergan Unities of botulinum toxin A (Botox®, Allergan) resuspended in 1 ml of saline in the trapeziometacarpal joint and custom-made thermoformed plastic splint to be worn for 48 hours after intra-articular injection then nightly
- Intra-articular saline and splinting (Type: ACTIVE_COMPARATOR): Ultrasound-guided injection of 1 ml of saline in the trapeziometacarpal joint and custom-made thermoformed plastic splint to be worn for 48 hours after intra-articular injection then nightly

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Lisdexamfetamine Dimesylate With Atomoxetine HCl in Attention-Deficit/Hyperactivity Disorder (ADHD) Subjects With an Inadequate Response to Methylphenidate

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has had an historical or current inadequate response to methylphenidate (MPH) treatment. Inadequate response includes but is not limited to the presence of some residual symptoms, with associated impairment inadequate duration of action and/or variability of symptom control, and/or Investigator feels that the subject may derive benefit from an alternative drug treatment to MPH therapy.~* Subject is a male or female aged 6-17 years inclusive at the time of consent~* Subject must meet Diagnostic and Statistical Manual of Mental Disorders, fourth edition. - Text Revision (DSM IV TR) criteria for a primary diagnosis of ADHD based on a detailed psychiatric evaluation~* Subject must have a baseline ADHD-RS-IV total score 28.~Exclusion Criteria:~* Subject has taken more than 1 MPH treatment (for example, 2 or more different MPH treatments). Examples include but are not limited to RITALIN immediate release (IR) and EQUASYM IR; MEDIKINET IR and CONCERTA; RITALIN long-acting LA and CONCERTA. Note: this does not include subjects who have taken IR MPH for dose titration on a short-term basis (for example, £4 weeks) with an adequate response~* In the Investigator's judgement, subject has failed to respond to more than 1 previous course(s) of MPH treatment. Failure to respond includes worsening of symptoms or no change/minimal improvement of symptoms.~* Subject has previously been exposed to STRATTERA or to amphetamine therapy~* Subject has previously demonstrated intolerable side effects to 1 MPH treatment which limited titration to acceptable efficacy or that required a decrease in dose resulting in unacceptable tolerability and/or efficacy~* Subject has a current, controlled (requiring a restricted medication) or uncontrolled, comorbid psychiatric diagnosis with significant symptoms such as any severe comorbid Axis II disorder or severe Axis I disorder or other symptomatic manifestations, such as agitated states, marked anxiety, or tension that, in the opinion of the examining physician, will contraindicate treatment with SPD489 or STRATTERA or confound efficacy or safety assessments.~* Subject has a conduct disorder. Oppositional Defiant Disorder is not exclusionary.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Lisdexamfetamine Dimesylate (Type: EXPERIMENTAL): None
- Atomoxetine Hydrochloride (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus Antibody Negative Participants

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Key Inclusion Criteria:~* Documented diagnosis of Relapsing Multiple Sclerosis (McDonald 2010 Criteria ).~* \<3 year disease duration.~* Must have an Expanded Disability Status Scale (EDSS) score from 0 to 4.0, inclusive.~* Anti-JCV antibody negative test within 6 months of Screening Visit.~* Must satisfy the approved therapeutic indications for Tysabri.~* Must be treatment-naïve to disease-modifying therapy (DMT) or have been treated with DMT (including but not limited to Avonex, Betaseron, Rebif, Copaxone, Extavia, or Gilenya) for ≤36 months total prior to date of informed consent.~* Decision to treat with Tysabri must precede enrollment.~Key Exclusion Criteria:~* Any prior treatment with Tysabri.~* Anti-JCV antibody positive at any timepoint prior to the Screening Visit.~* Contraindications to treatment with Tysabri as described in the US Prescribing Information.~* History of progressive multifocal leukoencephalopathy (PML) or other opportunistic infections, or an increased risk for such infections.~* History of diagnosis of Primary Progressive Multiple Sclerosis (PPM) and/or Secondary Progressive Multiple Sclerosis (SPMS).~* Receiving immunomodulatory or immunosuppressive therapy.~* Prior history of immunosuppressive use (mitoxantrone, azathioprine, methotrexate, cyclophosphamide, mycophenolate, cladribine, rituximab).~* Immunocompromised at the time of enrollment.~* Known active malignancies (subjects with cutaneous basal cell carcinoma that has been completely excised prior to study entry remain eligible).~* Women breastfeeding, pregnant, or planning to become pregnant; women who are not post-menopausal or surgically sterile who are unwilling to practice contraception.~* Inability to comply with study requirements.~NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Immunotherapy to Treat Advanced Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.~Inclusion Criteria:~* Advanced prostate cancer~* At least 1 bone metastasis~* Testosterone \< 50 ng/dl~* Prior treatment with docetaxel~Exclusion Criteria:~* Brain metastasis~* Autoimmune disease~* Known HIV, Hep B, or Hep C infection~* More than 2 prior systemic anticancer regimens for prostate cancer~* Prior treatment on BMS CA180227 for prostate cancer

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ipilimumab (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Intradermal RN1001 (Avotermin) in Elderly Subjects.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Clinically healthy, male and female subjects aged 60 years and over. All females will be at least 2 years post menopausal.~* Weight between 50 and 150kg or a body mass index within the permitted range for their height using Quetelet's index-weight (kg)/height²(m). The permitted index is between 15 - 35 kg/m2.~Exclusion Criteria:~* Subjects who on direct questioning and physical examination have a history or evidence of hypertrophic or keloid scarring or with tattoos or previous scars in the area to be biopsied.~* Subjects with a personal history of a bleeding disorder.~* Subjects with a skin disorder that is chronic or currently active and which the investigator considers will adversely affect the healing the acute wounds or involves the areas to be examined in this trial.~* Subjects with any clinically significant medical condition that would impair wound healing including renal, hepatic, haematological, neurological or immune disease.~* Subjects with a history of clinically significant drug hypersensitivity to lignocaine or allergy to surgical dressings to be used in this trial.~* Subjects with any clinically significant abnormality following review of pre trial laboratory data and physical examination (see above).~* Subjects who are taking, or have taken, any investigational drugs, long term oral, topical or inhaled corticosteroid therapy, hormone replacement therapy (HRT) or anti-coagulant drugs in the thirty days prior to Day 0.~* Subjects who have evidence of drug abuse.~* Subjects who are known to have or had serum hepatitis or who are carriers of the hepatitis B surface antigen or hepatitis C antibody. Subjects with previous vaccination against Hepatitis B are not excluded per se.~* Subjects who are known to have or had serum hepatitis or who are carriers of the hepatitis B core antibody and who show less than 10 units per litre of Anti-HBs.~* Subjects who have previously had a positive result to the test for HIV antibodies, or who admit to belonging to a high-risk group.~* In the opinion of the investigator, a subject who is not likely to complete the trial for what ever reason.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): 5ng Avotermin
- 2 (Type: EXPERIMENTAL): 50ng Avotermin
- 3 (Type: EXPERIMENTAL): 100ng Avotermin
- 4 (Type: PLACEBO_COMPARATOR): Placebo
- 5 (Type: NO_INTERVENTION): Standard Care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Effect of AZD5069 in Patients With Bronchiectasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male, or female of non-child bearing potential; ie, women who are permanently or surgically sterilised or post-menopausal.~* Aged 18 to 80 years inclusive at screening (Visit 1)~* Have a clinical diagnosis of idiopathic or post infective bronchiectasis as diagnosed with a historical high resolution computerised tomography (HRCT) or bronchogram~* Be sputum producers with a history of chronic expectoration on most days of most weeks of the year. Patients should have a history of spontaneously producing sputum on a daily basis and should be able to provide at least 2 of the 3 required baseline sputum samples with an average of 3 mL or more.~* Be on a stable treatment regimen, as judged by the investigator.~Exclusion Criteria:~* Any clinically significant disease or disorder~* Patients with other latent or chronic infections or at risk of infection within 90 days before Visit 2~* An acute exacerbation or acute respiratory infection (upper or lower) requiring oral steroids or antibiotics within 30 days prior to Visit 2~* An FEV1 of \<30% of predicted normal at Visit 1~* Patients who have received live or live-attenuated vaccine in the 2 weeks prior to dosing (Visit 2)~* Concomitant diagnosis of significant pulmonary disease other than bronchiectasis or COPD, including symptomatic asthma and allergic bronchopulmonary aspergillosis~* Bronchiectasis associated with a generalised immunodeficiency disorder, where manifestations other than bronchiectasis predominate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Treatment arm AZD5069
- 2 (Type: PLACEBO_COMPARATOR): Placebo dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Exploratory Multi-centre Trial In Patients With ET Treated With XAGRID®

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Patients must be able to understand and willing to participate in the study, and provide a personally dated and signed written informed consent form.~2. Patients must have a confirmed diagnosis of ET according to the World health Organisation's criteria.~3. ET patients who are uncontrolled, in the Investigator's opinion, by first-line (or previous) cytoreductive treatment for efficacy or tolerance reasons.~4. Patients who have either commenced treatment with anagrelide hydrochloride in the last 7 days or for whom a decision has been documented to commence treatment with anagrelide hydrochloride~Exclusion Criteria:~1. Patients for whom treatment with anagrelide hydrochloride is contraindicated, according to the current XAGRID SmPC.~2. Known or suspected intolerance or hypersensitivity to the product, closely related compounds, or any of the stated ingredients.~3. Patients participating in an interventional research study.~4. Patients on combination therapy or for whom there is an intention to treat with other cytoreductive agents e.g., hydroxyurea, interferon. Patients can however use aspirin and other anti-aggregatory products at the Investigator's discretion.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- JAK2 Positive Participants (Type: None): None
- JAK2 Negative Participants (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ultrasound-guided Serratus Plane Block for the Quality of Recovery After Modified Radical Mastectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients of American Society of Anesthesiologists' (ASA) Physical Status class I-II scheduled for first modified radical mastectomy were included.~Exclusion Criteria:~* Patients with chronic ethanol~* long-term use of psychotropic drugs (e.g. sedative drugs and antidepressant);~* contraindications for serratus plane block including coagulopathy, infection at the puncture site;~* unable to cooperate with this research due to cognitive impairment, psychopathy or not willing for the hospital follow-up;~* administration of other test drugs or joining in other clinical study in 3 months before our study;~* received radiotherapy or chemotherapy before surgery;~* other conditions not allocated for this study out of the researchers' consideration.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- group control (Type: PLACEBO_COMPARATOR): group control :Before induction of intravenous anesthesia, patients were received an ultrasound-guided serratus plane block, the serratus plane was injected with 0.9% Nacl 0.4ml/Kg.
- group SPB (Type: EXPERIMENTAL): group SPB:Before induction of intravenous anesthesia, patients were received an ultrasound-guided serratus plane block, the serratus plane was injected with 0.5% ropivacaine 0.4ml/Kg.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combination of Alemtuzumab and Rituximab at Low-doses in Refractory Chronic Graft-Versus-Host Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with chronic graft-versus-host disease.~* Patients over 18 years old.~* Patients who received first-line treatment with no response (failure), relapse or steroid dependance.~Exclusion Criteria:~* Patients with active bacterial or viral infections.~* Patients with hematologic disease progression.~* Patient's intolerance to drugs.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Alemtuzumab and rituximab (Type: EXPERIMENTAL): Patients with chronic GVHD after first-line therapy failure will receive Alemtuzumab at 10mg subcutaneously daily for 3 doses (days 1, 2 and 3) Rituximab at 100mg intravenously weekly for 4 doses (days 4, 11, 18 and 25. THE STUDY HAVE ONLY ONE ARM.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Primary & Booster Study in Infants to Demonstrate Non-inferiority, Persistence & Immunogenicity of Hib-MenC Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~Primary Phase:~* Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol should be enrolled in the study.~* healthy male or female subject between, and including, 6 and 12 weeks of age at the time of the first vaccination, born after a gestation period between and including 36 and 42 weeks.~* Written informed consent obtained from the parent or guardian of the subject prior to the study entry.~* Free of obvious health problems as established by medical history and clinical examination before entering into the study.~Booster Phase:~• Participation in primary phase of study.~Exclusion Criteria~Primary Phase:~* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) since birth or planned use during the study period.~* Chronic administration (defined as more than 14 days) of immunosuppressant or other immune-modifying drugs since birth.~* Planned administration/ administration of a vaccine not foreseen by the study protocol since birth, with exception of BCG.~* Previous vaccination against meningococcal serogroup C disease, diphtheria, tetanus, pertussis, polio, pneumococcal, Hepatitis B or Hib disease~* History of Haemophilus influenzae type b and /or meningococcal serogroup C disease.~* Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus infection.~* A family history of congenital or hereditary immunodeficiency.~* History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.~* Major congenital defects or serious chronic illness.~* History of any neurologic disorders or seizures.~* Acute disease at the time of enrolment.~* Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.~Additional Exclusion criteria for the Booster Phase:~• Previous booster vaccination with Hib and/or MenC and/or DTP containing and/or IPV containing and/or HepB containing vaccine(s).

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 12 Weeks
- Healthy Volunteers: t

Study Arms:
- Group Hib-MenC (Type: EXPERIMENTAL): Subjects receive 2 primary vaccination doses at 3 and 5 months of age and a booster dose at 11 months of age of Hib-MenC + Infanrix™ penta vaccines.
- Group NeisVac-C (Type: ACTIVE_COMPARATOR): Subjects receive 2 primary vaccination doses at 3 and 5 months of age and a booster dose at 11 months of age of NeisVac-C™ + Infanrix™ hexa vaccines.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Surgery With or Without Lymph Node Removal in Treating Older Women With Stage I Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically proven stage I, invasive breast cancer~* Hormone receptor status:~  * Estrogen receptor positive~ * Progesterone receptor positive or negative~PATIENT CHARACTERISTICS:~Age:~* 65 to 80~Sex:~* Female~Menopausal status:~* Postmenopausal~Performance status:~* Not specified~Life Expectancy:~* Not specified~Hematopoietic:~* Not specified~Hepatic:~* Not specified~Renal:~* Not specified~Other:~* No serious disease that would preclude surgery~* No other prior or concurrent malignancy except basal cell carcinoma or carcinoma in situ of the cervix~PRIOR CONCURRENT THERAPY:~* Not specified

- Gender: FEMALE
- Minimum Age: 65 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete